Skinhealth Systems Inc

Skinhealth Systems Inc (SKIN) Stock Analysis

$0.685

-0.006 (-0.94%)At close

Loading chart…
High
0.710
Open
0.690
VWAP
0.69
Vol
369.21K
Mkt Cap
234.90M
Low
0.673
Amount
254.50K
EV/EBITDA, TTM
6.38

SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals.

AI analysis of Skinhealth Systems Inc (SKIN)

buy

Beauty Health Co (SKIN) is a good buy right now due to its recent FDA clearance for the SkinStylus microneedling device, which strengthens its market position in a growing industry. The current price of $0.685 is significantly below the analyst price target of $2 from Roth Capital, indicating a potential upside of approximately 192%. Additionally, the stock has shown a 5-day change of +4.85%, suggesting positive momentum. However, the main risk is its high forward P/E ratio of 106.38, indicating that the stock is currently expensive relative to its expected earnings, which could limit upside if growth does not materialize as anticipated.

Valuation Metrics

The current forward P/E ratio for Skinhealth Systems Inc (SKIN) is 106.38, compared to its 5-year average forward P/E of 24.23.

Forward P/E

Fair
5Y Average P/E
24.23
Current P/E
106.38
Overvalued
184.98
Undervalued
-136.52

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
29.79
Current EV/EBITDA
6.38
Overvalued
70.94
Undervalued
-11.36

Forward P/S

Fair
5Y Average P/S
2.77
Current P/S
0.30
Overvalued
6.10
Undervalued
-0.55

Alphio AI Price Scenarios for SKIN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SKIN

$1.44

Scenario price

B

Base

Base · 50%SKIN

$1.26

Scenario price

B

Bear

Bear · 25%SKIN

$1.05

Scenario price

Whales holding SKIN

L

Linden Advisors LP

+ HoldingSKIN

-1.91%

3M Return

Events Timeline

2026-08-26 (ET)

09:30:00

SkinHealth Systems Launches Hydrafacial Impact Education Program

2026-07-07 (ET)

09:00:00

SkinHealth Systems Receives FDA Clearance for SkinStylus Microneedling Device

2026-04-22 (ET)

09:30:00

Beauty Health Company Rebrands to SkinHealth Systems

2026-03-12 (ET)

16:20:00

BeautyHealth Sees FY26 Adjusted EBITDA of $35M-$45M

16:10:00

Sees Q1 Adjusted EBITDA of $3.5M-$5.5M

News

SKIN FAQ — answered by Alphio AI

SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals. It operates in the Consumer Non-Cyclicals sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Beauty Health Co (SKIN) is a good buy right now due to its recent FDA clearance for the SkinStylus microneedling device, which strengthens its market position in a growing industry. The current price of $0.685 is significantly below the analyst price target of $2 from Roth Capital, indicating a potential upside of approximately 192%. Additionally, the stock has shown a 5-day change of +4.85%, suggesting positive momentum. However, the main risk is its high forward P/E ratio of 106.38, indicating that the stock is currently expensive relative to its expected earnings, which could limit upside if growth does not materialize as anticipated.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started